News
2026/10/10
JeYou Pharma's AR-NTD Inhibitor Clinical Trial Application Approved
Shanghai JeYou Pharmaceutical Technology Co., Ltd. announced that the clinical trial application for its self-developed AR-NTD inhibitor, the JMN-2205 tablet project, has been approved...
Details
06
2022/05
Innovative Drugs Go Global! Jeyou Pharma and ORION Announce Major Partnership
Shanghai Jeyou Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Jeyou Pharmaceutical”) has entered into an exclusive cooperation agreement with ORION CORPORATION (hereinafter referred to as “ORION”): ORION will obtain the rights to develop, manufacture, and commercialize Jeyou Pharmaceutical’s proprietary non-opioid analgesic (JMKX000623) outside the Greater China region, while Jeyou Pharmaceutical will retain all relevant rights to the drug within the Greater China region……
30
2021/11
Jeyou Pharma has licensed the rights to its KRAS inhibitor outside of China to Huya Bio
Shanghai Jeyou Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Jeyou Pharmaceutical”) has entered into an exclusive licensing agreement with Huya Bio International (hereinafter referred to as “Huya”), under which Jeyou Pharmaceutical will be responsible for the development of JMKX1899, a KRAS inhibitor with proprietary intellectual property rights, outside the Greater China region……